What the label lists and what reports show

Semaglutide side effects

Semaglutide's FDA label: “The most common adverse reactions reported in ≥5% of patients treated with OZEMPIC are: nausea, vomiting, diarrhea, abdominal pain and constipation.” FAERS holds 73,001 reports naming it through July 30, 2026; the reaction reported most often, leaving out the conditions it is used for, product-use terms and outcomes, is nausea (10,674 reports).

No generic listed
A presentation discontinued
Boxed warning

Check it at the source: the semaglutide FDA label on DailyMed (effective July 30, 2026, A-S Medication Solutions); the FDA FAERS public dashboard.

What does the patient leaflet say about side effects?

From the patient leaflet: What are the possible side effects of OZEMPIC?
OZEMPIC may cause serious side effects, including: • See “What is the most important information I should know about OZEMPIC?” • inflammation of your pancreas (pancreatitis). Stop using OZEMPIC and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back. • changes in vision. Tell your healthcare provider if you have changes in vision during treatment with OZEMPIC. • low blood sugar (hypoglycemia). Your risk for getting low blood sugar may be higher if you use OZEMPIC with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. […]

Source: FDA drug label, NDA209637 (Novo), as published by A-S Medication Solutions, effective July 30, 2026 (SPL set 42bdd912-2393-44c4-b7e0-47672ca28991), via openFDA; the full label on DailyMed

What does the label list?

From the label: adverse reactions
The most common adverse reactions reported in ≥5% of patients treated with OZEMPIC are: nausea, vomiting, diarrhea, abdominal pain and constipation.

A table the label prints in its adverse reactions section without a title; its column headings name the groups compared

(30 weeks)	Placebo N=129	OZEMPIC 0.5 mg N=127	OZEMPIC 1 mg N=130
Severe	0%	0%	0%
Documented symptomatic (≤70 mg/dL glucose threshold)	0%	1.6%	3.8%
Severe † or Blood Glucose Confirmed Symptomatic (≤56 mg/dL glucose threshold)	1.6%	0%	0%
Severe	0%	0%	1.5%
Documented symptomatic (≤70 mg/dL glucose threshold)	15.2%	16.7%	29.8%
Severe † or Blood Glucose Confirmed Symptomatic (≤56 mg/dL glucose threshold)	5.3%	8.3%	10.7%

Rows and numbers as the label prints them, under its own column headings (the first rows of a longer table where it runs on). A reaction in a trial table is not necessarily caused by the medicine, and trials differ from everyday use.

From the label: adverse reactions, continued
The following serious adverse reactions are described below or elsewhere in the prescribing information: • Risk of Thyroid C-cell Tumors [see Warnings and Precautions ( 5.1 )] • Acute Pancreatitis [see Warnings and Precautions ( 5.2) ] • Diabetic Retinopathy Complications [see Warnings and Precautions ( 5.3 )] • Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions ( 5.5 )] • Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions ( 5.6 )] • Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions ( 5.7 )] • Hypersensitivity Reactions [see Warnings and Precautions ( 5.8 )] • Acute Gallbladder Disease [see Warnings and Precautions ( 5.9 )] • Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions ( 5.10 )] The most common adverse reactions reported in ≥5% of patients treated with OZEMPIC are: nausea, vomiting, diarrhea, abdominal pain and constipation. …

Source: FDA drug label, NDA209637 (Novo), as published by A-S Medication Solutions, effective July 30, 2026 (SPL set 42bdd912-2393-44c4-b7e0-47672ca28991), via openFDA; the full label on DailyMed

What do FAERS reports show?

73,001 reports list semaglutide among the medicines taken, each a report of something that happened, not proof the medicine caused it; 1,270 are coded as a death and 14,338 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is. Reports rose sharply in 2025 (20,013, against a median of 3,515 a year): FAERS counts follow reporting, which news, litigation and label changes can drive, not how often a reaction happens. Of the 20 reactions below, 10 are named by the same term (in US spelling) in the label's adverse reactions, warnings or patient leaflet; a reaction the label does not name may still be there under another word, and a report does not show that the medicine caused it.

Reports received each year

The 25 most reported reactions

Nausea (named in the label)10,674
Off Label Use (a use or a product term, not a reaction)7,325
Vomiting (named in the label)6,964
Diarrhoea (named in the label)6,462
Decreased Appetite4,905
Constipation (named in the label)4,724
Weight Decreased4,487
Impaired Gastric Emptying3,558
Product Use In Unapproved Indication (a use or a product term, not a reaction)3,483
Blood Glucose Increased3,303
Headache (named in the label)3,099
Fatigue (named in the label)3,063
Abdominal Pain Upper3,039
Wrong Technique In Product Usage Process (a use or a product term, not a reaction)3,016
Weight Increased2,612
Dizziness (named in the label)2,587
Inappropriate Schedule Of Product Administration (a use or a product term, not a reaction)2,446
Abdominal Pain (named in the label)2,361
Asthenia1,991
Dehydration (named in the label)1,968
Malaise1,884
Illness1,724
Abdominal Distension1,691
Drug Ineffective (a use or a product term, not a reaction)1,666
Dyspepsia (named in the label)1,661

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026; reactions as MedDRA preferred terms

What next?

Semaglutide: the full record: label, generics, price, shortages, recalls
Report a side effect to the FDA: MedWatch
Side effects hub: the most reported medicines and reactions